Image

Our Mission

Provide the whole process service based on accurate detection for cell drugs from research and development to marketing

About Us

image
2018-2022
2018

BioSwan was founded

Patent applied for anti-CD19 CAR-T cell detection reagent

Participated in the first study of the CAR-T cell quality control organized by Center for Drug Evaluation, NMPA

2019

More than 20 Chinese CAR-T related enterprises adopted Bioswan products

Started clinical studies in companion diagnosis of CAR-T cellular therapies in Shanghai Tongji Hospital and the First Affiliated Hospital
of Zhejiang University

PCT application

2020

First companion diagnosis product for CAR-T cellular therapy that submitted for product classification in China

PHave clients from top international institutions, hospitals and pharmaceutical companies (MGH, MAYO,NIH,UPENN

1 new PCT application

2021

First companion diagnosis product for CAR-T cellular therapy that submitted registration in China

Participated in the drafting of China Expert Consensus on Clinical Management of Toxic and Side Effects of CAR-T Cell Therapies for NHL

Launched overall CAR-T clinical detection protocol (Certified Medical Laboratory, LDT)

Applied for US, European, Japanese patents

2022

The CAR-T flow cytometry kit passed the application for special review of National Innovative Medical Devices.

Customers and Partners
Image
Domestic Customers

Regulatory agencies

Class A hospitals

Large cellular product companies (CAR-T products have been approved in China)

CRO/CDMO

ICL

Overseas Customers

June Lab ( Lead by Prof. Carl June)

European University laboratories

Large hospitals in the U.S.

Large pharmaceutical companies in US

CRO and CDMO in US and Europe

ICLs in US

Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image